The LFIA platform also showed a trend of lower real-world sensitivity (0.67, 95% CI, 0.50 to 0.81) compared with laboratory approval sensitivity (0.99, 95% CI 0.90 to 0.99, Q=8.56, p 0.003).
← all excerpts
Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic.
1
—
—